However, it will be interesting to see in the future whether these PI3K targets are prognostic biomarkers in larger cohort of patients, which should also be justified by age, mutation status, sex, disease stages and induction pre-treatment; moreover, the clinical implications of key components within PI3K pathway identified in GSE51878 warrant further investigations in RNA sequencing data generated from relevant AML or CML models with knockdown of PROX1-AS1, SENCR, or LN892. The gene discussed is PIK3CG; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.